NCT04401020 - First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

March 2, 2024

Study Completion Date

March 17, 2026

Conditions

Neoplasm Malignant

Interventions

DRUG

SAR442257

Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion

Trial Locations (16)

Investigational Site Number : 2030002, Prague

Investigational Site Number : 7240006, Madrid

Investigational Site Number : 7240007, Madrid

Investigational Site Number : 7240001, Pamplona

University of Miami - Sylvester Comprehensive Cancer Center Site Number : 8400005, Miami

Investigational Site Number : 7240005, Santander

Investigational Site Number : 7240004, Valencia

Mayo Clinic of Rochester Site Number : 8400003, Rochester

Investigational Site Number : 2030003, Brno

Investigational Site Number : 2030001, Ostrava - Poruba

City of Hope Site Number : 8400001, Duarte

Investigational Site Number : 5780001, Oslo

Investigational Site Number : 5780101, Oslo

Investigational Site Number : 4100001, Seoul

Investigational Site Number : 4100002, Seoul

Investigational Site Number : 7240003, Badalona